Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing 177Lu-Based Peptide Receptor Radionuclide Therapy.

作者：S. Baur, Tristan Ruhwedel, Ekin Böke, Zuzanna Kobus, Gergana Lishkova, Christoph Wetz, H Amthauer, Christoph Roderburg, Frank Tacke, Julian M Rogasch, Wojciech Samek, Henning Jann, Jackie Ma, Johannes Eschrich · 发表于：PubMed · 年份：2026 · DOI：10.3390/cancers18081194 · 被引用次数：3 · 研究领域：Neuroendocrine Tumor Research Advances、Radiopharmaceutical Chemistry and Applications、Peptidase Inhibition and Analysis

: Multimodal deep learning combining SR-PET, CT, and laboratory biomarkers outperformed unimodal approaches for PFS prediction after PRRT. Upon external validation, such models may support risk-adapted follow-up strategies.